For example, GSK3368715, a PRMT1 inhibitor has been utilised in patients with B‐cell lymphoma, whilst several antagonists targeting PRMT5 have been investigated in many clinical trials for solid tumours and non‐Hodgkin lymphoma.30 Here, PRMT5 is linked to B-cell non-Hodgkin lymphoma.